Hematopoietic stem cell transplant (HSCT) is the preferred treatment for young patients with multiple myeloma (MM), but for older adults there is limited evidence on its effectiveness from clinical trials
The prognosis of patients with multiple myeloma has improved markedly over the last two decades. Des...
AbstractAutologous hematopoietic cell transplantation (AHCT) for plasma cell myeloma is performed le...
Objectives: ASCT is currently the “gold standard” first-line treatment for multiple myeloma patients...
Hematopoietic stem cell transplant (HSCT) is the preferred treatment for young patients with multipl...
We retrospectively studied 340 fit patients with multiple myeloma (MM) who underwent autologous stem...
In the past decade, the number of autologous hematopoietic stem cell transplants (Auto HSCT) for old...
In the past decade, the number of autologous hematopoietic stem cell transplants (Auto HSCT) for old...
Autologous hematopoietic cell transplantation (AHCT) for plasma cell myeloma is performed less often...
Autologous hematopoietic cell transplantation (AHCT) for plasma cell myeloma is performed less often...
Autologous hematopoietic cell transplantation (AHCT) for plasma cell myeloma is performed less often...
BackgroundConsolidative autologous hematopoietic stem cell transplantation (AHCT) is commonly used f...
Background: The aim of this study was to determine the value of upfront autologous transplantation (...
AbstractAutologous hematopoietic cell transplantation (AHCT) for plasma cell myeloma is performed le...
Introduction: HSCT is a curative option for many patients (pts) with hematological malignancies. Si...
Objectives: ASCT is currently the “gold standard” first-line treatment for multiple myeloma patients...
The prognosis of patients with multiple myeloma has improved markedly over the last two decades. Des...
AbstractAutologous hematopoietic cell transplantation (AHCT) for plasma cell myeloma is performed le...
Objectives: ASCT is currently the “gold standard” first-line treatment for multiple myeloma patients...
Hematopoietic stem cell transplant (HSCT) is the preferred treatment for young patients with multipl...
We retrospectively studied 340 fit patients with multiple myeloma (MM) who underwent autologous stem...
In the past decade, the number of autologous hematopoietic stem cell transplants (Auto HSCT) for old...
In the past decade, the number of autologous hematopoietic stem cell transplants (Auto HSCT) for old...
Autologous hematopoietic cell transplantation (AHCT) for plasma cell myeloma is performed less often...
Autologous hematopoietic cell transplantation (AHCT) for plasma cell myeloma is performed less often...
Autologous hematopoietic cell transplantation (AHCT) for plasma cell myeloma is performed less often...
BackgroundConsolidative autologous hematopoietic stem cell transplantation (AHCT) is commonly used f...
Background: The aim of this study was to determine the value of upfront autologous transplantation (...
AbstractAutologous hematopoietic cell transplantation (AHCT) for plasma cell myeloma is performed le...
Introduction: HSCT is a curative option for many patients (pts) with hematological malignancies. Si...
Objectives: ASCT is currently the “gold standard” first-line treatment for multiple myeloma patients...
The prognosis of patients with multiple myeloma has improved markedly over the last two decades. Des...
AbstractAutologous hematopoietic cell transplantation (AHCT) for plasma cell myeloma is performed le...
Objectives: ASCT is currently the “gold standard” first-line treatment for multiple myeloma patients...
DOI
Add to ORKG